Related Experiment Video

Updated: May 13, 2026

Cell Type-specific Gene Expression Profiling in the Mouse Liver
10:06

Cell Type-specific Gene Expression Profiling in the Mouse Liver

Published on: September 17, 2019

α-Fetoprotein promoter-driven Cre/LoxP-switched RNA interference for hepatocellular carcinoma tissue-specific target

Yuan-Fei Peng1, Ying-Hong Shi, Zhen-Bin Ding

  • 1Department of Liver Surgery, Liver Cancer Institute, Zhongshan Hospital, Fudan University, Shanghai, PR China.

Plos One
|March 8, 2013
PubMed
Abstract

Insights

This study developed an alpha-fetoprotein promoter (AFP)-driven Cre/LoxP short hairpin RNA (shRNA) system for hepatocellular carcinoma (HCC) therapy. This targeted RNA interference (RNAi) system effectively suppressed tumor growth and enhanced sorafenib treatment in HCC models.

Area of Science:

  • Oncology
  • Molecular Biology
  • Gene Therapy

Background:

  • Hepatocellular carcinoma (HCC) therapy faces challenges with RNA interference (RNAi) due to limited cellular targets and sustained efficacy.
  • Developing tissue-specific RNAi systems is crucial for effective HCC treatment.

Purpose of the Study:

  • To engineer and evaluate an HCC tissue-specific RNA interference (RNAi) system.
  • To investigate the potential of this system for hepatocellular carcinoma (HCC) treatment.

Main Methods:

  • Constructed two HCC-specific RNAi systems: AFP-miRNA and AFP-Cre/LoxP-shRNA, targeting Beclin 1.
  • Assessed system effectiveness and specificity in HCC cell lines and mouse models.
  • Evaluated the AFP-Cre/LoxP-shRNA system targeting Atg5 in combination with sorafenib.

Main Results:

  • The AFP-Cre/LoxP-shRNA system demonstrated high HCC specificity and efficient gene knockdown.
  • Intratumoral administration of the AFP-Cre/LoxP-shRNA system effectively silenced target genes in vivo.
  • The AFP-Cre/LoxP-shRNA-Atg5 system enhanced sorafenib-induced apoptosis and suppressed tumor growth.

Conclusions:

  • Successfully established an efficient HCC tissue-specific RNAi system (AFP-Cre/LoxP-shRNA).
  • This system offers a viable tool for targeted RNAi therapy in HCC.
  • The developed system holds promise as a novel therapeutic strategy for HCC.

More Related Videos

Dual CRISPR-Interference Strategy for Targeting Synthetic Lethal Interactions Between Non-Coding RNAs in Cancer Cells07:23

Dual CRISPR-Interference Strategy for Targeting Synthetic Lethal Interactions Between Non-Coding RNAs in Cancer Cells

Published on: May 30, 2025

Development and Optimization of A Human Hepatocellular Carcinoma Patient-Derived Organoid Model for Potential Target Identification and Drug Discovery07:25

Development and Optimization of A Human Hepatocellular Carcinoma Patient-Derived Organoid Model for Potential Target Identification and Drug Discovery

Published on: August 18, 2023

Related Concept Videos

Conservative Site-specific Recombination and Phase Variation02:53

Conservative Site-specific Recombination and Phase Variation

Because the DNA segments are cut and reorganized in a direction-specific manner, site-specific recombination has emerged as an efficient genetic engineering technique. Flippase and Cyclization recombinases or Flp and Cre, respectively, are two members of the tyrosine recombinase family derived from bacteriophages, that are used to mediate site-specific DNA insertions, deletions, and targeted expression of proteins in mammalian cell lines.
The recognition sites for Cre recombinase called LoxP...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Experimental RNAi02:15

Experimental RNAi

RNA interference (RNAi) is a cellular mechanism that inhibits gene expression by suppressing its transcription or activating the RNA degradation process. The mechanism was discovered by Andrew Fire and Craig Mello in 1998 in plants. Today, it is observed in almost all eukaryotes, including protozoa, flies, nematodes, insects, parasites, and mammals. This precise cellular mechanism of gene silencing has been developed into a technique that provides an efficient way to identify and determine the...